Our News on Newswise

Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis

Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
11-Nov-2020 9:30 AM EST Add to Favorites

Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments

Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments
11-Nov-2020 7:30 AM EST Add to Favorites


See All News

Our Experts on Newswise

Our experts are coming soon...

Our YouTube Videos

Youtube feed not yet configured. Is this your Newswise member page? Contact member@newswise.com to configure this module.

About

About section not configured. Is this your member page? Login to edit, or contact member@newswise.com to configure this module.

Contacts

Marissa Picerno
Communications Specialist

marissa.picerno@intelliatx.com

Twitter

close
0.15778